callfree now
US Toll Free:
Regular US:
UK Phone:
Perform search

Welcome to our website

Welcome to our website! We are glad to offer you the most popular generic medications that successfully substitute costly brand name drugs today. We are sure that these high quality generic medicines will meet the exacting standards you expect from us now and in the future.

Trial Packs

Trial Packs
Viagra + Cialis + Levitra

Our benefits:

World wide shipping Discreet packaging Privacy guarantee Widest product selection 24/7 customer support

Live Support

Live Support
Live Support

Your cart

$0.00 (0 items)   Checkout

Categories list

What are generics? Medications by A/Z Pharmaceutical news and reviews



Choose your language:


We accept:


Our billing is certified by:
Secure shopping certificates

product xeloda is not found!

Sorry we do not carry xeloda at this time.




  • 2 High-Flying Biotechs Face a New Hurdle - Motley Fool

    2 High-Flying Biotechs Face a New HurdleMotley FoolIn addition to the aforementioned difference in the progression of the disease, the control group in the regorafenib group got the best supporting care while the perifosine trial will compare perifosine in combination with Roche's Xeloda to Xeloda .

  • Roche plant spared from sale runs into GMP issues - FiercePharma Manufacturing

    Roche plant spared from sale runs into GMP issuesFiercePharma ManufacturingThe Florence, SC, plant manufactures intermediates and active pharmaceutical ingredients (API) used in Tamiflu, Xeloda, Xenical and Valcyte as well as the PEG reagent for Pegasys.

  • Roche posts strong 2011 profits, upbeat on 2012 - The Pharma Letter

    BloombergRoche posts strong 2011 profits, upbeat on 2012The Pharma LetterDemand for key cancer medicines Herceptin (trastuzumab), MabThera/Rituxan (rituximab), Xeloda (capecitabine) and Tarceva (erlotinib) continued to grow, and initial sales of the new targeted skin cancer medication Zelboraf (vemurafenib), launched in the .

  • Roche Holding's CEO Discusses Q4 2011 Results - Earnings Call Transcript - Seeking Alpha

    Roche Holding's CEO Discusses Q4 2011 Results - Earnings Call TranscriptSeeking AlphaThe Avastin decline I have commented on and you can see also quite nice growth for Xeloda and Tarceva.

  • 2 High-Flying Biotechs Face a New Hurdle - DailyFinance

    2 High-Flying Biotechs Face a New HurdleDailyFinanceIn addition to the aforementioned difference in the progression of the disease, the control group in the regorafenib group got best supporting care, while the perifosine trial will compare perifosine in combination with Roche's Xeloda to Xeloda alone.